Cannabidiol Use in Inflammatory Bowel Disease: Insights From a Gastroenterology Outpatient Population
Cannabidiol (CBD) is increasingly used for symptom relief in chronic conditions, yet its role in inflammatory bowel disease (IBD) remains underexplored. We surveyed 229 IBD patients and found that 10.5% used CBD, primarily for anxiety (54.2%), insomnia (41.7%), and pain (41.7%). Among users, 87.5% perceived benefit. Most users were female, and one-third were on biologics. These findings highlight the growing interest in alternative therapies and the need for further research on CBD's safety, efficacy, and clinical guidance in IBD care.
Authors
- Royce Perera
- Emily Glazer
- Karina Fatakhova (ORCID: https://orcid.org/0000-0001-8581-1248)
- Ramona Rajapakse (ORCID: https://orcid.org/0000-0002-1187-8404)
- Benjamin Glazebnik
- Greg Haggerty (ORCID: https://orcid.org/0000-0002-3256-616X)
- Sapphire Perera
- Hassam Ali
- Lindsey Donnelly
- Pratik Patel
- Muhammad Jahanzaib Khan
Institutions
- Vassar College (US)
- East Carolina University (US)
- Cornell University (US)
- University of South Florida (US)
- John T. Mather Memorial Hospital (US)
- New York University (US)
Publication Details
- Journal
- JGH Open
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1002/jgh3.70402
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00